FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. What is offered is a dementia drug containing donepezil or its pharmaceutically acceptable salt, and memantin or its pharmaceutically acceptable salt. The drug contains a prolonged-release portion containing a pH-independent polymer substance and a pH-dependent polymer substance. The content of the pH-dependent polymer substance at 1 weight portion of the pH-independent polymer substance in each prolonged-release portion makes totally 0.1 to 10 weight portions.
EFFECT: invention provides the composition containing 2 types of the dementia drugs in which the drug release is controlled to ensure the combined effect in dementia treatment.
9 cl, 5 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ANTIDEMENTIA DRUG STABILISATION | 2005 |
|
RU2401125C2 |
| SLOW-RELEASE MATRIX PREPARATION CONTAINING BASE AGENT OR ITS SALT AND METHOD FOR MAKING THEREOF | 2005 |
|
RU2390354C2 |
| TAMZULOSIN TABLETS | 2002 |
|
RU2311903C2 |
| COMPOSITION CONTAINING FINE DISPERSED LONG RELEASING PARTICLES FOR QUICK-DISPOSABLE IN BUCCAL CAVERN TABLETS | 2002 |
|
RU2245136C2 |
| SYSTEMS OF MEDICATION DELIVERY, INCLUDING SOLID SOLUTIONS OF WEAK-BASE MEDICATIONS | 2007 |
|
RU2434630C2 |
| PHARMACEUTICAL FORMULATION WITH CONTROLLED-RELEASE ACTIVE SUBSTANCE | 2004 |
|
RU2447884C2 |
| COMBINED COMPOSITION CONTAINING METFORMIN OF SUSTAINED RELEASE AND INHIBITOR HMG-CoA-REDUCTASE OF IMMEDIATE RELEASE | 2014 |
|
RU2651460C2 |
| SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION CONTAINING RIVASTIGMINE | 2016 |
|
RU2727721C2 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| CONTROLLED-RELEASE FORMULATION | 2006 |
|
RU2385712C2 |
